NGNE vs PRAX vs ACAD vs RARE vs SRPT

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 8x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate Neurogene Inc. (NGNE) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Sarepta Therapeutics, Inc.

is actually cheaper at 5. 9x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ACADIA Pharmaceuticals Inc.

(ACAD) delivered a total return of +6. 6%, compared to -85. 7% for Neurogene Inc. (NGNE). Over 10 years, the gap is even starker: SRPT returned +13. 2% versus NGNE's -80. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.

(ACAD) is the lower-risk stock at 1. 11β versus Neurogene Inc. 's 2. 00β — meaning NGNE is approximately 79% more volatile than ACAD relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -79. 5% for RARE. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sarepta Therapeutics, Inc.

(SRPT) trades at 5. 9x forward P/E versus 55. 6x for ACADIA Pharmaceuticals Inc. — 49. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NGNE: 124. 2% to $69. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 11)). Neurogene Inc. (NGNE) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -23. 4%, NGNE: -80. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NGNE is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; RARE is a small-cap high-growth stock; SRPT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.